A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO-CONTROLLED RANDOMIZED STUDY WITH DOSE-UP FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Ritlecitinib (Primary)
- Indications Alopecia areata
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 18 Mar 2025 New trial record